Compare NOVT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOVT | NAMS |
|---|---|---|
| Founded | 1968 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 3.5B |
| IPO Year | 1999 | N/A |
| Metric | NOVT | NAMS |
|---|---|---|
| Price | $116.63 | $28.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $133.00 | $46.75 |
| AVG Volume (30 Days) | 391.1K | ★ 804.5K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $521,290,000.00 | N/A |
| Revenue This Year | $8.71 | $25.64 |
| Revenue Next Year | $6.47 | $530.85 |
| P/E Ratio | $81.06 | ★ N/A |
| Revenue Growth | ★ 35.49 | N/A |
| 52 Week Low | $98.27 | $14.06 |
| 52 Week High | $149.95 | $42.00 |
| Indicator | NOVT | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 32.18 | 34.30 |
| Support Level | $111.49 | $23.48 |
| Resistance Level | $126.36 | $37.43 |
| Average True Range (ATR) | 7.01 | 1.77 |
| MACD | -2.72 | -0.42 |
| Stochastic Oscillator | 0.94 | 0.75 |
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.